Physician profile
Benjamin H Levy
NPI 1922245737
$3,357.93
in general payments reported to CMS, 2019-2025
24 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $77.82 · 2021: $19.43 · 2022: $150 · 2023: $907 · 2024: $669 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.50 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $581.62 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $516.96 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $265.41 | 2020-2024 | |
| Allergan, INC. | $244.52 | 2019 | |
| Ardelyx, INC. | $184.26 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $183.86 | 2019-2021 | |
| Lucid Diagnostics INC. | $150.32 | 2022 | |
| Janssen Scientific Affairs, LLC | $150.07 | 2025 | Tremfya |
| Daiichi Sankyo INC. | $143.41 | 2023 | Enhertu |
| Qol Medical, LLC | $137.61 | 2023 | Sucraid |
| Endogastric Solutions, INC | $136.32 | 2024 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.42 | 2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $121.53 | 2019 | |
| Phathom Pharmaceuticals, INC. | $103.53 | 2025 | Voquezna |
| Laborie Medical Technologies Corp. | $69.86 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $49.24 | 2019 | |
| Ucb, INC. | $39.23 | 2019 | |
| Redhill Biopharma INC. | $35.26 | 2020 | |
| Pfizer INC. | $30.64 | 2019-2020 | |
| Genzyme Corporation | $21.73 | 2019 | |
| Philips North America LLC | $20.89 | 2019 | |
| Olympus America INC. | $16.56 | 2024 | Evis X1 Video System Center |
| Avanir Pharmaceuticals, INC. | $15.88 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.